In a patient with a history of alcohol addiction who suddenly develops hyperhidrosis, bradyphasia, resting tremor, and gait disturbance, what is the most likely diagnosis and appropriate acute management?

Alcohol Withdrawal Syndrome with Wernicke's Encephalopathy

This patient is experiencing alcohol withdrawal syndrome (AWS) with features highly suggestive of Wernicke's encephalopathy, requiring immediate thiamine administration followed by benzodiazepine therapy and inpatient management.

Most Likely Diagnosis

The constellation of hyperhidrosis (sweating), bradyphasia (slow speech), resting tremor, and gait disturbance in a patient with sudden alcohol cessation points to two concurrent conditions:

1. Alcohol Withdrawal Syndrome (AWS) - manifesting with tremor, sweating, and autonomic hyperactivity
2. Wernicke's Encephalopathy - indicated by gait disturbance (ataxia) and bradyphasia (mental status changes)

The sudden onset within 6-24 hours after last alcohol intake is classic for AWS 1. The gait disturbance and altered mental function strongly suggest thiamine deficiency-related Wernicke's encephalopathy, which is common in patients with alcohol use disorder 2.

Immediate Acute Management Algorithm

Step 1: Thiamine First (Critical)

• Administer thiamine 100-500 mg IV/IM immediately before any glucose-containing fluids 2
• Continue 100-300 mg/day for prevention, or 100-500 mg/day for 12-24 weeks if Wernicke's is confirmed 2
• Critical pitfall: Never give IV glucose before thiamine, as this can precipitate acute Wernicke's encephalopathy 2

Step 2: Assess Severity

• This patient requires inpatient admission given the serious neurological complications (gait disturbance, mental status changes) 2, 1
• CIWA-Ar score >8 indicates moderate AWS; ≥15 indicates severe AWS 1

Step 3: Benzodiazepine Therapy

Benzodiazepines are the gold standard for AWS treatment, reducing withdrawal symptoms and preventing seizures and delirium tremens 1, 3.

Choice of benzodiazepine depends on liver function:

• If NO liver disease or mild disease: Use long-acting benzodiazepines

  • Diazepam 5-10 mg PO/IV every 6-8 hours 2
  • Chlordiazepoxide 25-100 mg PO every 4-6 hours 2
  • These provide better protection against seizures and delirium 1

• If advanced liver disease/cirrhosis present: Use intermediate-acting benzodiazepines

  • Lorazepam 1-4 mg PO/IV/IM every 4-8 hours 2, 1
  • Safer in hepatic dysfunction, elderly, or respiratory compromise 2, 1
  • Start at 6-12 mg/day and taper after symptom resolution 2

Dosing strategy: Use symptom-triggered regimen rather than fixed-dose schedule to prevent drug accumulation 1

Step 4: Supportive Care

• IV fluids and electrolyte correction (especially magnesium) 2
• Monitor for progression to delirium tremens, seizures, or cardiovascular instability
• Comfortable, quiet environment 2

Step 5: Monitoring

• Daily monitoring for up to 5 days after last drink 2, 1
• Watch for seizures (typically 12-48 hours post-cessation), delirium tremens (typically after 48-72 hours) 1

Key Clinical Pearls

Wernicke's Encephalopathy Recognition: The classic triad (ataxia, ophthalmoplegia, confusion) is present in only 10% of cases. Gait disturbance alone with alcohol history warrants empiric thiamine 2.

Benzodiazepine Duration: Limit benzodiazepines to 10-14 days maximum due to abuse potential in patients with alcohol use disorder 1.

Psychiatric Consultation: Recommended for evaluation, acute management, and long-term abstinence planning 2.

Alternative Agents: While carbamazepine, baclofen, and phenobarbital have been studied, benzodiazepines remain first-line with the strongest evidence for preventing life-threatening complications 1, 3.

Disposition

Admit to inpatient unit given serious complications (neurological symptoms suggesting Wernicke's encephalopathy) 2, 1. Severe AWS with delirium, seizures, or significant comorbidities requires inpatient treatment to prevent mortality from delirium tremens, which carries up to 50% mortality if untreated 1.